“Permissive AKI” with treatment of heart failure

Chirag R. Parikh, Steven G. Coca

Research output: Contribution to journalComment/debate

Abstract

Renin–angiotensin–aldosterone system inhibitors have proven clinical benefit in management of patients with heart failure with reduced ejection fraction. However, there are no guidelines to manage decline in kidney function that occurs with initiation and titration of renin–angiotensin–aldosterone system agents during management of heart failure. We discuss the complex interplay of kidney function and heart failure in the presence of renin–angiotensin–aldosterone system agents and suggest a clinical algorithm for management of acute decline in kidney function.

Original languageEnglish (US)
Pages (from-to)1066-1068
Number of pages3
JournalKidney International
Volume96
Issue number5
DOIs
StatePublished - Nov 2019

Fingerprint

Treatment Failure
Heart Failure
Kidney
Renal Insufficiency
Guidelines

ASJC Scopus subject areas

  • Nephrology

Cite this

“Permissive AKI” with treatment of heart failure. / Parikh, Chirag R.; Coca, Steven G.

In: Kidney International, Vol. 96, No. 5, 11.2019, p. 1066-1068.

Research output: Contribution to journalComment/debate

Parikh, Chirag R. ; Coca, Steven G. / “Permissive AKI” with treatment of heart failure. In: Kidney International. 2019 ; Vol. 96, No. 5. pp. 1066-1068.
@article{c7abd92ca13d416f8ef2a81f6b162164,
title = "“Permissive AKI” with treatment of heart failure",
abstract = "Renin–angiotensin–aldosterone system inhibitors have proven clinical benefit in management of patients with heart failure with reduced ejection fraction. However, there are no guidelines to manage decline in kidney function that occurs with initiation and titration of renin–angiotensin–aldosterone system agents during management of heart failure. We discuss the complex interplay of kidney function and heart failure in the presence of renin–angiotensin–aldosterone system agents and suggest a clinical algorithm for management of acute decline in kidney function.",
author = "Parikh, {Chirag R.} and Coca, {Steven G.}",
year = "2019",
month = "11",
doi = "10.1016/j.kint.2019.07.003",
language = "English (US)",
volume = "96",
pages = "1066--1068",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - “Permissive AKI” with treatment of heart failure

AU - Parikh, Chirag R.

AU - Coca, Steven G.

PY - 2019/11

Y1 - 2019/11

N2 - Renin–angiotensin–aldosterone system inhibitors have proven clinical benefit in management of patients with heart failure with reduced ejection fraction. However, there are no guidelines to manage decline in kidney function that occurs with initiation and titration of renin–angiotensin–aldosterone system agents during management of heart failure. We discuss the complex interplay of kidney function and heart failure in the presence of renin–angiotensin–aldosterone system agents and suggest a clinical algorithm for management of acute decline in kidney function.

AB - Renin–angiotensin–aldosterone system inhibitors have proven clinical benefit in management of patients with heart failure with reduced ejection fraction. However, there are no guidelines to manage decline in kidney function that occurs with initiation and titration of renin–angiotensin–aldosterone system agents during management of heart failure. We discuss the complex interplay of kidney function and heart failure in the presence of renin–angiotensin–aldosterone system agents and suggest a clinical algorithm for management of acute decline in kidney function.

UR - http://www.scopus.com/inward/record.url?scp=85073665396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073665396&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2019.07.003

DO - 10.1016/j.kint.2019.07.003

M3 - Comment/debate

C2 - 31648696

AN - SCOPUS:85073665396

VL - 96

SP - 1066

EP - 1068

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -